| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.46B | 1.45B | 1.42B | 1.39B | 733.04M | 442.89M |
| Gross Profit | 347.65M | 366.12M | 354.27M | 382.28M | 124.79M | -50.87M |
| EBITDA | 239.00M | 306.40M | 274.58M | 238.40M | 124.83M | -74.93M |
| Net Income | -98.44M | -4.24M | -78.02M | -87.17M | -184.86M | -391.73M |
Balance Sheet | ||||||
| Total Assets | 5.55B | 5.69B | 5.82B | 6.13B | 6.26B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 223.16M | 206.65M | 183.75M | 41.04M | 58.52M | 124.27M |
| Total Debt | 2.57B | 2.57B | 2.64B | 2.71B | 2.76B | 2.79B |
| Total Liabilities | 2.95B | 2.91B | 2.97B | 3.05B | 3.10B | 2.81B |
| Stockholders Equity | 2.51B | 2.70B | 2.76B | 3.00B | 3.16B | 3.26B |
Cash Flow | ||||||
| Free Cash Flow | 370.38M | 275.00M | 236.20M | 162.00M | -13.06M | -326.79M |
| Operating Cash Flow | 287.70M | 275.00M | 236.20M | 278.75M | 70.77M | -201.78M |
| Investing Cash Flow | -78.92M | -92.83M | 142.02M | -109.39M | -81.57M | 250.12M |
| Financing Cash Flow | -120.93M | -158.22M | -236.85M | -209.34M | -33.25M | 31.08M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | $1.79B | 33.52 | 3.98% | 5.41% | 0.95% | -8.40% | |
65 Neutral | $1.10B | 150.10 | 1.49% | 8.31% | -0.58% | -83.32% | |
64 Neutral | $2.75B | 15.80 | 5.41% | 8.81% | 0.57% | -13.58% | |
64 Neutral | $1.28B | 24.11 | 4.58% | 3.99% | 4.29% | 141.01% | |
58 Neutral | $1.80B | 1,890.00 | 0.88% | 4.04% | 3.04% | -98.77% | |
54 Neutral | $1.22B | ― | -3.74% | 0.37% | 0.99% | -360.58% |
On December 3, 2025, Pebblebrook Hotel Trust completed the sale of the 752-room Westin Michigan Avenue Chicago for $72.0 million. The proceeds from this sale will be used to reduce outstanding debt and preferred equity, repurchase common shares, and support other capital allocation priorities. This transaction, along with a previous sale, has allowed the company to reduce its debt by $100 million. Despite the sale, Pebblebrook’s updated fourth-quarter and full-year 2025 outlook remains largely unchanged, as the reduction in interest expenses is expected to offset the loss of hotel-level EBITDA.
On November 19, 2025, Pebblebrook Hotel Trust completed the sale of the 133-room Montrose at Beverly Hills in West Hollywood, California, for $44.25 million. The proceeds from this sale are intended for general corporate purposes, such as reducing outstanding debt, repurchasing shares, and supporting other capital allocation priorities to enhance long-term shareholder value. This transaction is not expected to affect the company’s current fourth-quarter or full-year 2025 outlook. Additionally, Pebblebrook has another hotel under contract for sale at $72 million, expected to close in the fourth quarter, subject to customary conditions.
On October 21, 2025, Pebblebrook Hotel‘s Board authorized a new share repurchase program of up to $150 million, terminating the previous program. This initiative allows the company to buy back shares at its discretion, based on various market and economic factors, without a set expiration date, potentially impacting the company’s stock value and shareholder returns.
On September 16, 2025, Pebblebrook Hotel Trust announced a private offering of $400 million in 1.625% Convertible Senior Notes due 2030, which closed on September 18, 2025. The proceeds were used to repurchase $400 million of its 1.75% Convertible Senior Notes due 2026 and approximately 4.3 million common shares. This strategic financial maneuver aims to manage the company’s debt profile and potentially reduce dilution of common shares, enhancing its market positioning and financial flexibility.
On September 15, 2025, Pebblebrook Hotel Trust announced that its Board of Trustees has authorized and declared cash dividends for its common and preferred shares for the quarter ending September 30, 2025. The dividends, which include $0.01 per common share and varying amounts for preferred shares, are set to be paid on October 15, 2025, to shareholders of record as of September 30, 2025. This decision reflects the company’s ongoing commitment to providing returns to its shareholders and may impact its financial strategy and market positioning.